Trial Outcomes & Findings for MRI and PET/FMISO In Assessing Tumor Hypoxia in Patients With Newly Diagnosed Glioblastoma Multiforme (NCT NCT00902577)
NCT ID: NCT00902577
Last Updated: 2019-04-08
Results Overview
Overall Survival (OS) was evaluated every 3 months through end of the study (up to 5 years). A variety of continuous quantitative (functional) imaging features measuring abnormal tumor vasculature (MRI) and hypoxia (FMISO) were evaluated at baseline for their association with Survival time. Features include PET Hypoxia measures: Peak standardized uptake values (SUVpeak); maximum tumor:blood ratio (T/Bmax); and Hypoxia Volume (HV) DCE MRI perfusion measures: Mean/median volume transfer constant for gadolinium between blood plasma and the tissue extravascular extracellular space (ktrans) DSC MRI tumor vasculature: Normalized Relative cerebral blood volume (nRCBV); and Cerebral blood flow (CBF) DWI MRI magnitude of diffusion of water through tissue (cell density): Apparent diffusion coefficient (ADC) using low and high Gaussian distributions
COMPLETED
PHASE2
50 participants
"assessed from baseline up to 5 years, survival status at 1-year reported
2019-04-08
Participant Flow
Fifty patients with newly diagnosed GBM were enrolled from 11 academic centers in the United States.
All participants were scheduled to receive both FMISO and MRI (DCE, DSC, DWI, MRS) imaging two weeks before initiation of chemoradiotherapy with temozolomide
Participant milestones
| Measure |
Newly Diagnosed Glioblastoma Multiforme Patients
Patients with Newly diagnosed GBM scheduled to have FMISO Positron Emission Tomography (PET) two weeks before initiation of chemoradiotherapy with temozolomide, with diagnostic DCE/DSE/DWI MRI
|
|---|---|
|
Overall Study
STARTED
|
50
|
|
Overall Study
FMISO/PET
|
38
|
|
Overall Study
DCE MRI
|
31
|
|
Overall Study
DSE MRI
|
37
|
|
Overall Study
DWI MRI
|
39
|
|
Overall Study
COMPLETED
|
42
|
|
Overall Study
NOT COMPLETED
|
8
|
Reasons for withdrawal
| Measure |
Newly Diagnosed Glioblastoma Multiforme Patients
Patients with Newly diagnosed GBM scheduled to have FMISO Positron Emission Tomography (PET) two weeks before initiation of chemoradiotherapy with temozolomide, with diagnostic DCE/DSE/DWI MRI
|
|---|---|
|
Overall Study
Withdrawal by Subject
|
6
|
|
Overall Study
FMISO production failure
|
2
|
Baseline Characteristics
MRI and PET/FMISO In Assessing Tumor Hypoxia in Patients With Newly Diagnosed Glioblastoma Multiforme
Baseline characteristics by cohort
| Measure |
Newly Diagnosed Glioblastoma Multiforme Patients
n=42 Participants
42 eligible, consented patients with newly diagnosed GBM who received both FMISO-PRT and MRI imaging two weeks before initiation of chemoradiotherapy with temozolomide
|
|---|---|
|
Age, Continuous
|
57 years
STANDARD_DEVIATION 9.07 • n=99 Participants
|
|
Sex: Female, Male
Female
|
15 Participants
n=99 Participants
|
|
Sex: Female, Male
Male
|
27 Participants
n=99 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
5 Participants
n=99 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
36 Participants
n=99 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
1 Participants
n=99 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
1 Participants
n=99 Participants
|
|
Race (NIH/OMB)
Asian
|
1 Participants
n=99 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=99 Participants
|
|
Race (NIH/OMB)
Black or African American
|
2 Participants
n=99 Participants
|
|
Race (NIH/OMB)
White
|
38 Participants
n=99 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=99 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
|
Median Tumor Volume
|
14.94 mm^3
n=99 Participants
|
PRIMARY outcome
Timeframe: "assessed from baseline up to 5 years, survival status at 1-year reportedPopulation: FMISO-PET identifies the primary analysis population containing participants with interpretable FMISO images.The Evaluable study population consisted of enrolled GBM patients having an FMISO-PET procedure. Additional groups include functional MRI, with available/interpretable images.
Overall Survival (OS) was evaluated every 3 months through end of the study (up to 5 years). A variety of continuous quantitative (functional) imaging features measuring abnormal tumor vasculature (MRI) and hypoxia (FMISO) were evaluated at baseline for their association with Survival time. Features include PET Hypoxia measures: Peak standardized uptake values (SUVpeak); maximum tumor:blood ratio (T/Bmax); and Hypoxia Volume (HV) DCE MRI perfusion measures: Mean/median volume transfer constant for gadolinium between blood plasma and the tissue extravascular extracellular space (ktrans) DSC MRI tumor vasculature: Normalized Relative cerebral blood volume (nRCBV); and Cerebral blood flow (CBF) DWI MRI magnitude of diffusion of water through tissue (cell density): Apparent diffusion coefficient (ADC) using low and high Gaussian distributions
Outcome measures
| Measure |
Evaluable
n=42 Participants
42 participants with imaging (FMISO-PET, DCE/DSC/DWI MRI)
|
FMISO-PET
n=38 Participants
Quantitative PET measurements Hypoxic Volume (HV) Max tumor:blood ratio (TBmax) Peak Standardized uptake Values (SUVpeak)
|
DSC MRI
n=37 Participants
Quantitative DSC measurements:
Normalized rCBV \[Relative cerebral blood volume\] Normalized rCBF\[Relative cerebral blood flow\]
|
DCE MRI
n=31 Participants
Quantitative DCE measurements Mean vascular permeability (ktrans) Median Ktrans
|
DWI-MRI
n=39 Participants
Apparent diffusion coefficient (ADC) Low and High
|
|---|---|---|---|---|---|
|
Association of Baseline FMISO PET and MRI Features With OS as Assessed Using Cox-regression Model
OS-1 Alive
|
25 Participants
|
22 Participants
|
24 Participants
|
20 Participants
|
24 Participants
|
|
Association of Baseline FMISO PET and MRI Features With OS as Assessed Using Cox-regression Model
OS-1 Death
|
17 Participants
|
16 Participants
|
13 Participants
|
11 Participants
|
15 Participants
|
SECONDARY outcome
Timeframe: assessed from baseline up to 5 years, progression status at months 6 and 9 reportedDisease progression was defined by Macdonald criteria. PFS was evaluated every 3months through the end of study (up to 5yrs), features were measured at baseline. Quantitative imaging features measuring abnormal tumor vasculature (MRI) and hypoxia (FMISO) were evaluated for their association with TTP (cox model) and to discriminate between responders and non-responders at 6 and 9 mos (PFS6 and PFS9) (logistic) Features include PET Hypoxia measures: Peak standardized uptake values (SUVpeak); maximum tumor:blood ratio (T/Bmax); and Hypoxia Volume (HV) DCE MRI perfusion measures: Mean/median volume transfer constant for gadolinium between blood plasma and the tissue extravascular extracellular space (ktrans) DSC MRI tumor vasculature: Normalized Relative cerebral blood volume (nRCBV); and Cerebral blood flow (CBF) DWI MRI magnitude of diffusion of water through tissue (cell density): Apparent diffusion coefficient (ADC) using low and high Gaussian distributions
Outcome measures
| Measure |
Evaluable
n=42 Participants
42 participants with imaging (FMISO-PET, DCE/DSC/DWI MRI)
|
FMISO-PET
n=38 Participants
Quantitative PET measurements Hypoxic Volume (HV) Max tumor:blood ratio (TBmax) Peak Standardized uptake Values (SUVpeak)
|
DSC MRI
n=37 Participants
Quantitative DSC measurements:
Normalized rCBV \[Relative cerebral blood volume\] Normalized rCBF\[Relative cerebral blood flow\]
|
DCE MRI
n=31 Participants
Quantitative DCE measurements Mean vascular permeability (ktrans) Median Ktrans
|
DWI-MRI
n=39 Participants
Apparent diffusion coefficient (ADC) Low and High
|
|---|---|---|---|---|---|
|
Association of Baseline FMISO PET and MRI Features With Time-to-Progression (TTP)
6 month Progression Status · Progression Free
|
29 Participants
|
26 Participants
|
27 Participants
|
20 Participants
|
28 Participants
|
|
Association of Baseline FMISO PET and MRI Features With Time-to-Progression (TTP)
6 month Progression Status · Progressed
|
13 Participants
|
12 Participants
|
10 Participants
|
11 Participants
|
11 Participants
|
|
Association of Baseline FMISO PET and MRI Features With Time-to-Progression (TTP)
9 Month Progression Status · Progression Free
|
19 Participants
|
17 Participants
|
18 Participants
|
12 Participants
|
18 Participants
|
|
Association of Baseline FMISO PET and MRI Features With Time-to-Progression (TTP)
9 Month Progression Status · Progressed
|
23 Participants
|
21 Participants
|
19 Participants
|
19 Participants
|
21 Participants
|
SECONDARY outcome
Timeframe: Baseline and retest within 1 to 7 days after (but prior to the start of therapy)Population: Analysis will be performed SUVmax and SUV Peak, average and maximum values, across patients and by target tumor.
Reproducibility, defined as the variation of repeated measurements in an experiment performed under the same conditions, will be measured as the within subject coefficient of variation with upper an lower repeatability coefficients (LRC, URC) computed as percents from log-transformed data, per Velaquez, et al (J Nucl Med. 2009 Oct;50(10):1646-54. doi: 10.2967/jnumed.109.063347. Epub 2009 Sep 16. PMID: 19759105 ). Where Within Subject Coefficient of Variation (wCV) is a percentage defined as wCV(%)=100\* (exp( SD\[ld\]/√2) - 1) and LRC and URC are calculated as: RC=100 (exp(±1.96 SD\[ld\]) -1). here SD\[ld\] is the standard deviation of the difference of the log-transformed PET measurements. These bounds provide an estimate of the lower and upper bounds of percent change observed between scans for each measurement.
Outcome measures
| Measure |
Evaluable
n=29 Participants
42 participants with imaging (FMISO-PET, DCE/DSC/DWI MRI)
|
FMISO-PET
Quantitative PET measurements Hypoxic Volume (HV) Max tumor:blood ratio (TBmax) Peak Standardized uptake Values (SUVpeak)
|
DSC MRI
Quantitative DSC measurements:
Normalized rCBV \[Relative cerebral blood volume\] Normalized rCBF\[Relative cerebral blood flow\]
|
DCE MRI
Quantitative DCE measurements Mean vascular permeability (ktrans) Median Ktrans
|
DWI-MRI
Apparent diffusion coefficient (ADC) Low and High
|
|---|---|---|---|---|---|
|
Reproducibility of the Baseline FMISO PET Uptake Parameters as Assessed by Baseline "Test" and "Retest" PET Scans
SUVmax : Average across all lesions by participant
|
7.03 Within Subj. Coefficient of Variation %
Interval -17.18 to 20.74
|
—
|
—
|
—
|
—
|
|
Reproducibility of the Baseline FMISO PET Uptake Parameters as Assessed by Baseline "Test" and "Retest" PET Scans
SUVmax : Maximum across all lesions by participant
|
9.60 Within Subj. Coefficient of Variation %
Interval -22.43 to 28.92
|
—
|
—
|
—
|
—
|
|
Reproducibility of the Baseline FMISO PET Uptake Parameters as Assessed by Baseline "Test" and "Retest" PET Scans
SUVmax : Target Lesion
|
8.18 Within Subj. Coefficient of Variation %
Interval -19.59 to 24.36
|
—
|
—
|
—
|
—
|
|
Reproducibility of the Baseline FMISO PET Uptake Parameters as Assessed by Baseline "Test" and "Retest" PET Scans
SUVpeak: Average across all lesions by participant
|
7.08 Within Subj. Coefficient of Variation %
Interval -17.27 to 20.88
|
—
|
—
|
—
|
—
|
|
Reproducibility of the Baseline FMISO PET Uptake Parameters as Assessed by Baseline "Test" and "Retest" PET Scans
SUVpeak: Maximum across all lesions by participant
|
9.20 Within Subj. Coefficient of Variation %
Interval -21.65 to 27.63
|
—
|
—
|
—
|
—
|
|
Reproducibility of the Baseline FMISO PET Uptake Parameters as Assessed by Baseline "Test" and "Retest" PET Scans
SUVpeak: Target Lesion
|
8.24 Within Subj. Coefficient of Variation %
Interval -19.71 to 24.55
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: At baselinePearson correlation coefficient will be used to quantify the correlation between T/Bmax, the maximum tissue-to-blood ratio activity value, and T/Cmax, the tissue-to-cerebellum activite value Since T/Cmax does not requiring blood sampling and is image derived, a high correlation would indicate that T/Cmax could be an advantageous surrogate for T/Bmax.
Outcome measures
| Measure |
Evaluable
n=38 Participants
42 participants with imaging (FMISO-PET, DCE/DSC/DWI MRI)
|
FMISO-PET
Quantitative PET measurements Hypoxic Volume (HV) Max tumor:blood ratio (TBmax) Peak Standardized uptake Values (SUVpeak)
|
DSC MRI
Quantitative DSC measurements:
Normalized rCBV \[Relative cerebral blood volume\] Normalized rCBF\[Relative cerebral blood flow\]
|
DCE MRI
Quantitative DCE measurements Mean vascular permeability (ktrans) Median Ktrans
|
DWI-MRI
Apparent diffusion coefficient (ADC) Low and High
|
|---|---|---|---|---|---|
|
Correlation Between T/Cmax and T/Bmax
|
0.98 correlation coefficient
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: baselinePopulation: Seventeen participants from four sites had analyzable 3D MRSI datasets acquired on Philips, GE or Siemens scanners at either 1.5T or 3T. MRSI data were analyzed using LCModel to quantify metabolites N-acetylaspartate (NAA), creatine (Cr), choline (Cho), and lactate (Lac)
Correlation between MRS markers and MR imaging markers and PET markers of tumor hypoxia MRS markers include: NAA/Cho, Cho/Cr, Lac/Cr, and Lac/NAA measured within tumor and at the periphery. MR imaging markers of vascularity include: CBV, CBF, and ktrans PET tumor hypoxia marker: SUVmax
Outcome measures
| Measure |
Evaluable
n=17 Participants
42 participants with imaging (FMISO-PET, DCE/DSC/DWI MRI)
|
FMISO-PET
n=17 Participants
Quantitative PET measurements Hypoxic Volume (HV) Max tumor:blood ratio (TBmax) Peak Standardized uptake Values (SUVpeak)
|
DSC MRI
n=17 Participants
Quantitative DSC measurements:
Normalized rCBV \[Relative cerebral blood volume\] Normalized rCBF\[Relative cerebral blood flow\]
|
DCE MRI
n=17 Participants
Quantitative DCE measurements Mean vascular permeability (ktrans) Median Ktrans
|
DWI-MRI
Apparent diffusion coefficient (ADC) Low and High
|
|---|---|---|---|---|---|
|
Correlation Between MRS Markers and MR Imaging Markers of Vascularity as Well as Between MRS Markers and PET Markers of Tumor Hypoxia
NAA/Cho Tumor
|
-0.38 correlation coefficient
|
-0.41 correlation coefficient
|
-0.08 correlation coefficient
|
-.33 correlation coefficient
|
—
|
|
Correlation Between MRS Markers and MR Imaging Markers of Vascularity as Well as Between MRS Markers and PET Markers of Tumor Hypoxia
NAA/Cho Periphery
|
-0.33 correlation coefficient
|
-0.34 correlation coefficient
|
0.14 correlation coefficient
|
-0.41 correlation coefficient
|
—
|
|
Correlation Between MRS Markers and MR Imaging Markers of Vascularity as Well as Between MRS Markers and PET Markers of Tumor Hypoxia
Cho/Cr Tumor
|
0.24 correlation coefficient
|
0.28 correlation coefficient
|
-0.2 correlation coefficient
|
0.03 correlation coefficient
|
—
|
|
Correlation Between MRS Markers and MR Imaging Markers of Vascularity as Well as Between MRS Markers and PET Markers of Tumor Hypoxia
Cho/Cr Periphery
|
0.17 correlation coefficient
|
0.20 correlation coefficient
|
-0.27 correlation coefficient
|
0.11 correlation coefficient
|
—
|
|
Correlation Between MRS Markers and MR Imaging Markers of Vascularity as Well as Between MRS Markers and PET Markers of Tumor Hypoxia
Lac/Cr Tumor
|
-0.27 correlation coefficient
|
-0.25 correlation coefficient
|
-0.06 correlation coefficient
|
-0.29 correlation coefficient
|
—
|
|
Correlation Between MRS Markers and MR Imaging Markers of Vascularity as Well as Between MRS Markers and PET Markers of Tumor Hypoxia
Lac/Cr Periphery
|
-0.09 correlation coefficient
|
-0.11 correlation coefficient
|
0.10 correlation coefficient
|
-0.15 correlation coefficient
|
—
|
|
Correlation Between MRS Markers and MR Imaging Markers of Vascularity as Well as Between MRS Markers and PET Markers of Tumor Hypoxia
Lac/NAA Tumor
|
-0.02 correlation coefficient
|
-0.01 correlation coefficient
|
0.23 correlation coefficient
|
-0.18 correlation coefficient
|
—
|
|
Correlation Between MRS Markers and MR Imaging Markers of Vascularity as Well as Between MRS Markers and PET Markers of Tumor Hypoxia
Lac/NAA Periphery
|
-0.01 correlation coefficient
|
-0.01 correlation coefficient
|
0.33 correlation coefficient
|
-0.04 correlation coefficient
|
—
|
OTHER_PRE_SPECIFIED outcome
Timeframe: Baseline, every 3 months through study completion (up to 5 years for progression and survivorship)Disease progression was defined by Macdonald criteria. Survival and Progression were evaluated every 3months and at the end of study (up to 5 years) and time to event evaluated.
Outcome measures
| Measure |
Evaluable
n=42 Participants
42 participants with imaging (FMISO-PET, DCE/DSC/DWI MRI)
|
FMISO-PET
Quantitative PET measurements Hypoxic Volume (HV) Max tumor:blood ratio (TBmax) Peak Standardized uptake Values (SUVpeak)
|
DSC MRI
Quantitative DSC measurements:
Normalized rCBV \[Relative cerebral blood volume\] Normalized rCBF\[Relative cerebral blood flow\]
|
DCE MRI
Quantitative DCE measurements Mean vascular permeability (ktrans) Median Ktrans
|
DWI-MRI
Apparent diffusion coefficient (ADC) Low and High
|
|---|---|---|---|---|---|
|
Overall and Progression Free Survival
Median OS time
|
408 days
Interval 316.0 to 642.0
|
—
|
—
|
—
|
—
|
|
Overall and Progression Free Survival
Median PFS
|
258 days
Interval 190.0 to 335.0
|
—
|
—
|
—
|
—
|
OTHER_PRE_SPECIFIED outcome
Timeframe: baselineThe FMISO image data were normalized by the average blood activity to produce pixel level tissue-to-blood ratio (T/B) values for all image slices. And the severity of the hypoxia was determined by the pixel with the maximum T/B value (TBmax). FMISO SUVpeak was determined as the average SUV from a 1 cm circular ROI centered over the hottest pixel. Since FMISO selectively binds to hypoxic tissues, SUVpeak within a region provides a measure of tumor hypoxia.
Outcome measures
| Measure |
Evaluable
n=38 Participants
42 participants with imaging (FMISO-PET, DCE/DSC/DWI MRI)
|
FMISO-PET
Quantitative PET measurements Hypoxic Volume (HV) Max tumor:blood ratio (TBmax) Peak Standardized uptake Values (SUVpeak)
|
DSC MRI
Quantitative DSC measurements:
Normalized rCBV \[Relative cerebral blood volume\] Normalized rCBF\[Relative cerebral blood flow\]
|
DCE MRI
Quantitative DCE measurements Mean vascular permeability (ktrans) Median Ktrans
|
DWI-MRI
Apparent diffusion coefficient (ADC) Low and High
|
|---|---|---|---|---|---|
|
SUVpeak and T/Bmax as Measures of Tumor Hypoxia
SUVpeak
|
2.49 ratio
Standard Deviation 0.89
|
—
|
—
|
—
|
—
|
|
SUVpeak and T/Bmax as Measures of Tumor Hypoxia
T/Bmax
|
2.13 ratio
Standard Deviation 0.77
|
—
|
—
|
—
|
—
|
OTHER_PRE_SPECIFIED outcome
Timeframe: baselineThe hypoxic volume (HV) was determined as the volume of pixels in the tumor on in the FMISO\\PET with a tumor to blood activity ratio ≥ 1.2. HV is a measure of the spatial extent of tumor hypoxia (in milliliters)
Outcome measures
| Measure |
Evaluable
n=38 Participants
42 participants with imaging (FMISO-PET, DCE/DSC/DWI MRI)
|
FMISO-PET
Quantitative PET measurements Hypoxic Volume (HV) Max tumor:blood ratio (TBmax) Peak Standardized uptake Values (SUVpeak)
|
DSC MRI
Quantitative DSC measurements:
Normalized rCBV \[Relative cerebral blood volume\] Normalized rCBF\[Relative cerebral blood flow\]
|
DCE MRI
Quantitative DCE measurements Mean vascular permeability (ktrans) Median Ktrans
|
DWI-MRI
Apparent diffusion coefficient (ADC) Low and High
|
|---|---|---|---|---|---|
|
Hypoxic Volume as a Measure of Tumor Hypoxia
|
14.21 milliliters
Standard Deviation 11.61
|
—
|
—
|
—
|
—
|
OTHER_PRE_SPECIFIED outcome
Timeframe: baselinePopulation: Participants having a usable FMISO\\PET and DWI\\MRI scans
Apparent Diffusion Coefficient (ADC) measures water diffusion through tissue (mm\^2/s). Cerebral infarction leads to diffusion restriction resulting in a low ADC signal in the infarcted area. A double Gaussian mixed model was fit to the ADC histogram and the mean of the lower and the mean of the higher ADC curves were evaluated
Outcome measures
| Measure |
Evaluable
n=39 Participants
42 participants with imaging (FMISO-PET, DCE/DSC/DWI MRI)
|
FMISO-PET
Quantitative PET measurements Hypoxic Volume (HV) Max tumor:blood ratio (TBmax) Peak Standardized uptake Values (SUVpeak)
|
DSC MRI
Quantitative DSC measurements:
Normalized rCBV \[Relative cerebral blood volume\] Normalized rCBF\[Relative cerebral blood flow\]
|
DCE MRI
Quantitative DCE measurements Mean vascular permeability (ktrans) Median Ktrans
|
DWI-MRI
Apparent diffusion coefficient (ADC) Low and High
|
|---|---|---|---|---|---|
|
DWI Apparent Diffusion Coefficient (ADC)
Low
|
0.99 mm^2/s
Standard Deviation 0.15
|
—
|
—
|
—
|
—
|
|
DWI Apparent Diffusion Coefficient (ADC)
High
|
1.48 mm^2/s
Standard Deviation 0.39
|
—
|
—
|
—
|
—
|
OTHER_PRE_SPECIFIED outcome
Timeframe: baselinePopulation: Evaluable participants with both usable FMISO\\PET and DSC\\MRI.
Relative cerebral blood volume (RCBV) maps, computed from the integral of ∆R2\*(t), were corrected for leakage effects and normalized to normal appearing white matter (nRCBV); nRCBV provides a measure of tumor vasculature Cerebral blood flow (CBF) maps were was normalized to the mean of the region of interest (ROI) in normal appearing white matter (nCBF); nCBF provides a measure of vascular permeability and perfusion
Outcome measures
| Measure |
Evaluable
n=37 Participants
42 participants with imaging (FMISO-PET, DCE/DSC/DWI MRI)
|
FMISO-PET
Quantitative PET measurements Hypoxic Volume (HV) Max tumor:blood ratio (TBmax) Peak Standardized uptake Values (SUVpeak)
|
DSC MRI
Quantitative DSC measurements:
Normalized rCBV \[Relative cerebral blood volume\] Normalized rCBF\[Relative cerebral blood flow\]
|
DCE MRI
Quantitative DCE measurements Mean vascular permeability (ktrans) Median Ktrans
|
DWI-MRI
Apparent diffusion coefficient (ADC) Low and High
|
|---|---|---|---|---|---|
|
Normalized Relative Cerebral Blood Volume (nRCBV) and Normalized Cerebral Blood Flow (nCBF)
nRCBV
|
3.13 ratio
Standard Deviation 1.86
|
—
|
—
|
—
|
—
|
|
Normalized Relative Cerebral Blood Volume (nRCBV) and Normalized Cerebral Blood Flow (nCBF)
nCBF
|
3.36 ratio
Standard Deviation 2.02
|
—
|
—
|
—
|
—
|
OTHER_PRE_SPECIFIED outcome
Timeframe: baselinePopulation: Evaluable patients with usable FMISO\\PET and DCE\\MRI
ktrans is a measure of vascular permeability and reflects the rate of gadolinium moves from plasma to extravascular extracellular space (predominantly though blood flow and capillary leakage), which can be represented by the mean or median rate. Mean \& Median ktrans within subject were computed using a matrix-based linearization method to fit tissue ∆R1(t) to the extended Tofts model. The mean across subjects is presented below (Mean (Mean-ktrans) and Mean(Median-Ktrans))
Outcome measures
| Measure |
Evaluable
n=31 Participants
42 participants with imaging (FMISO-PET, DCE/DSC/DWI MRI)
|
FMISO-PET
Quantitative PET measurements Hypoxic Volume (HV) Max tumor:blood ratio (TBmax) Peak Standardized uptake Values (SUVpeak)
|
DSC MRI
Quantitative DSC measurements:
Normalized rCBV \[Relative cerebral blood volume\] Normalized rCBF\[Relative cerebral blood flow\]
|
DCE MRI
Quantitative DCE measurements Mean vascular permeability (ktrans) Median Ktrans
|
DWI-MRI
Apparent diffusion coefficient (ADC) Low and High
|
|---|---|---|---|---|---|
|
Summary of Mean and Median Ktrans Across Participants.
Mean kTrans
|
0.04 1/min
Standard Deviation 0.03
|
—
|
—
|
—
|
—
|
|
Summary of Mean and Median Ktrans Across Participants.
Median kTrans
|
0.03 1/min
Standard Deviation 0.07
|
—
|
—
|
—
|
—
|
Adverse Events
Evaluable Cases
Diagnostic PET (Using FMISO)
Diagnostic MRI (DCE MRI)
Diagnostic MRI (DSE MRI)
Diagnostic MRI (DWI MRI)
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place